|
Aurobindo Pharma Ltd., through
its wholly owned subsidiary Agile Pharma B.V,
Netherlands, has entered into Share Purchase
Agreement with Jerim B.V. and Jonghoud
International B.V. to acquire Netherlands based
generic pharmaceutical company, Pharmacin
International B.V. |
|
Under the terms of the share
purchase agreement, Agile Pharma B.V. has
acquired 100% of the shares of Pharmacin
International B.V. from Jerim B.V. and Jonghoud
International B.V. |
|
Pharmacin is a profit making
generic pharmaceutical company with a sale of
over Euro 6 million for the year ended Dec 2006,
with a CAGR of over 30%. Pharmacin is engaged in
the business of
supply and licensing of generic
pharmaceuticals in Netherlands and in select key
markets in Europe. Pharmacin
owns several product
dossiers/market authorizations and IPR. |
|
Pharmacin has a broad product
portfolio in three key segments – CNS, CVS and
Gasteroenterologicals and the dossiers support
over 200 product registrations for 63 customers
in Netherlands and Europe. Pharmacin has a reach
into most parts of Europe. In addition,
Pharmacin has continuously invested in enhancing
the product portfolio and certain key product
registrations are awaited in the coming months
augmenting the business. |
|
Pharmacin has established
relationships within the industry and has
obtained substantial market coverage in Europe.
Aurobindo expects to build on these
relationships to participate in the generic
pharmaceuticals value chain. The product
portfolio of Aurobindo, the manufacturing and
R&D capabilities are expected to help strengthen
and grow the relationships of Pharmacin.
Aurobindo would stand to benefit as this
acquisition would provide an opportunity to
expand into several markets in Europe with a
dependable infrastructure and proven
relationships. |
|
This is Aurobindo’s second
acquisition in Europe, after acquiring Milpharm
Limited in UK in early 2006. Aurobindo believes
that such acquisitions reduce the time to market
and enhance the relationships in the generic
value chain in addition to building a broad and
formidable product portfolio. |
|
Motilal Oswal Investment Advisors
Private Limited, was the lead advisor to
Aurobindo Pharma Ltd on the transaction. |
|
About Pharmacin |
|
The company originally started as
a sole proprietor company in the year 1986 in
Netherlands and later, on May 29, 1991 has
become a private limited liability company. It
possesses several IPRs and MAs for generic
pharmaceutical products, which are valid and
subsisting in European Markets. Pharmacin has a
dynamic marketing, distribution and regulatory
team and has built good relationships with
leading generic pharmaceutical companies in key
markets in Europe. Pharmacin cGMP warehouses and
offices are close to Rotterdam, a strategic
distribution location in Europe. |
|
About Aurobindo Pharma Limited: |
|
Aurobindo Pharma Limited (www.aurobindo.com),
headquartered at Hyderabad, India, manufactures
generic pharmaceuticals and active
pharmaceutical ingredients. The company’s robust
product portfolio is spread over 6 major
therapeutic/product areas encompassing
(Antibiotics, Anti-Retrovirals, CVS/ Statins/Diabetology,
CNS, Gastro/Uro/Kidney therapeutics, Anti
fungal/ allergics/respiratory) around 65
Betalactam APIs and 123 Non-Betalactam APIs.
The Company markets its products
in over 100 countries. The company has filed
over 65 ANDAs and 88 DMFs for the USA market, in
addition to several filings in other countries.
The company has received approvals for several
facilities from leading regulatory agencies like
US FDA, UK MHRA, WHO, Health Canada, MCC South
Africa. |
For further information,
please contact:
Investor Relations
Aurobindo Pharma Limited
Plot # 2, Maitri Vihar | Ameerpet
Hyderabad - 500 038 |India
Phone (Board): +91 40 5572 5000
Email : ir@aurobindo.com |
|
|
|
|
PRESS
ROOM
